Impact of comorbidity assessment methods to predict non-cancer mortality risk in cancer patients: a retrospective observational study using the National Health Insurance Service claims-based data in Korea

被引:3
|
作者
Lee, Sanghee [1 ]
Chang, Yoon Jung [1 ,2 ]
Cho, Hyunsoon [1 ]
机构
[1] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Canc Control & Populat Hlth, 323 Ilsan Ro, Goyang 10408, South Korea
[2] Natl Canc Ctr, Natl Canc Survivorship Ctr, Natl Canc Control Inst, Goyang, South Korea
基金
新加坡国家研究基金会;
关键词
Comorbidity; Cancer; Claims data; Charlson comorbidity index; Non-cancer; Mortality; Prognosis prediction;
D O I
10.1186/s12874-021-01257-2
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Cancer patients' prognoses are complicated by comorbidities. Prognostic prediction models with inappropriate comorbidity adjustments yield biased survival estimates. However, an appropriate claims-based comorbidity risk assessment method remains unclear. This study aimed to compare methods used to capture comorbidities from claims data and predict non-cancer mortality risks among cancer patients. Methods Data were obtained from the National Health Insurance Service-National Sample Cohort database in Korea; 2979 cancer patients diagnosed in 2006 were considered. Claims-based Charlson Comorbidity Index was evaluated according to the various assessment methods: different periods in washout window, lookback, and claim types. The prevalence of comorbidities and associated non-cancer mortality risks were compared. The Cox proportional hazards models considering left-truncation were used to estimate the non-cancer mortality risks. Results The prevalence of peptic ulcer, the most common comorbidity, ranged from 1.5 to 31.0%, and the proportion of patients with >= 1 comorbidity ranged from 4.5 to 58.4%, depending on the assessment methods. Outpatient claims captured 96.9% of patients with chronic obstructive pulmonary disease; however, they captured only 65.2% of patients with myocardial infarction. The different assessment methods affected non-cancer mortality risks; for example, the hazard ratios for patients with moderate comorbidity (CCI 3-4) varied from 1.0 (95% CI: 0.6-1.6) to 5.0 (95% CI: 2.7-9.3). Inpatient claims resulted in relatively higher estimates reflective of disease severity. Conclusions The prevalence of comorbidities and associated non-cancer mortality risks varied considerably by the assessment methods. Researchers should understand the complexity of comorbidity assessments in claims-based risk assessment and select an optimal approach.
引用
收藏
页数:9
相关论文
共 46 条